Daiichi Sankyo's TROP2 ADC has been approved for market launch in the United States.

Daiichi Sankyo's TROP2 ADC has been approved for market launch in the United States.

On January 17 (local time in the United States), Daiichi Sankyo announced the approval of Datroway® (datopotamab deruxtecan) for marketing in the United States, for the treatment of adult patients with HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) unresectable or metastatic breast cancer who have previously received endocrine therapy and chemotherapy. The above indication for Datroway® was approved in Japan on December 27, 2024, and registration applications in other countries/regions (EU, China, and others) are under review. This drug is the second antibody-drug conjugate designed using Daiichi Sankyo's DXd ADC technology platform to be approved for marketing in the United States, following Enhertu® (trastuzumab deruxtecan).

20

2025

/

01

Roche China has been named a "Top Employer in China" for nine consecutive years, ranking in the top ten.

Roche China has been named a "Top Employer in China" for nine consecutive years, ranking in the top ten.

On January 16, the internationally recognized Top Employers Institute released the "Top Employers in China 2025" list. Roche China stood out with an excellent score of 16 perfect marks among 156 cross-industry certified companies, ranking in the top ten for the ninth consecutive year. Notably, Roche China's human resource practices in the four key areas of employee well-being, recognition and rewards, talent development, and learning and development are particularly remarkable, fully demonstrating Roche China's value proposition of "people-oriented."

17

2025

/

01

JPM2025 Concludes: Undercurrents Among Pharmaceutical Giants, China's Innovation "Involution"

JPM2025 Concludes: Undercurrents Among Pharmaceutical Giants, China's Innovation "Involution"

The New Year for the biopharmaceutical industry in 2025 does not start on January 1st, but rather begins with people flocking to San Francisco. A wave of investors and corporate executives gather at the JP Morgan Conference to map out a roadmap for 2025 and assess and discuss the prospects in the financial and political arenas.

18

2025

/

01

Looking Ahead to 2025: Five Key Highlights of the Global Biopharmaceutical Industry

Looking Ahead to 2025: Five Key Highlights of the Global Biopharmaceutical Industry

In the field of new drug development, weight loss drugs are entering the vast areas of cardiovascular and metabolic diseases, becoming a major focus after traditional specialty drugs such as oncology, immunology, and rare disease therapies. At the same time, the overall industrial environment is changing—although the funding environment for investment and mergers and acquisitions seems to be warming up, the healthcare systems that have not fully adapted to the logic of innovative drugs struggle to support the returns on these innovations. As a result, many countries' healthcare systems are embarking on reform, with increasing patient empowerment. On the other hand, AI drug development, which once left Chinese investors feeling confused, is playing an increasingly important role in global healthcare services, and relevant application regulations are expected to be introduced by 2025.

21

2025

/

01

Innovative drug commercialization, how to grab the stock, seek incremental? 2024CHDC-Conference Glimpse

Innovative drug commercialization, how to grab the stock, seek incremental? 2024CHDC-Conference Glimpse

At present, the supply of innovative drugs in China is becoming more and more abundant, the competition is becoming more and more fierce, the product life cycle is shortened, and the battle of channels has become the "decisive game" for the commercialization of innovative drugs ". On the one hand, "difficulty in entering the hospital" has become a commonplace problem. On the other hand, the rapid growth of retail pharmacy channels outside the hospital has brought a way to break the situation for the commercialization of innovative drugs.

30

2024

/

09

Focus on Cell Therapy Gene Therapy AstraZeneca continues to seek new cooperation opportunities in China

Focus on Cell Therapy Gene Therapy AstraZeneca continues to seek new cooperation opportunities in China

From September 27th to 28th, the "2024 AstraZeneca China R & D Day-Reshaping the Life Track of Patients" chronic diseases and rare diseases special event was successfully held in Shanghai.

30

2024

/

09

Yi Fang Bio won the case of Mirati's technical secrets in the first instance.

Yi Fang Bio won the case of Mirati's technical secrets in the first instance.

On September 29, Yipang Biology issued a notice announcing that the company had received the "Civil Judgment" (Case No.:(2022) Shanghai 73 Zhimin Chu No. 1130) issued by the Shanghai Intellectual Property Court, regarding Mirati Medical (Mirati Therapeutics, hereinafter referred to as "Milati Company" or "Plaintiff") sued the company, the company's wholly-owned subsidiary, the U.S. interested party, and the company's director XING DAI (Daixing) for infringement of Milati Company and Yare Biotechnology Secrets. The court's first-instance judgment rejected all the plaintiff's claims.

30

2024

/

09

From ADC to XDC: Wave Surge, Innovation Far Away

From ADC to XDC: Wave Surge, Innovation Far Away

Antibody-drug conjugates (Antibody-drug Conjugates,ADCs) are currently one of the most active innovative drug tracks. Since 2022, there have been more than 140 global licensing collaborations and acquisitions around ADC drugs, with a cumulative total of more than $150 billion in potential transactions. In the cold winter of medicine, the ADC track bucked the trend and made great progress all the way.

29

2024

/

09

< 123 >